153 related articles for article (PubMed ID: 29945729)
1. Analysis of the QuantiFERON-CMV assay, CMV viraemia and antiviral treatment following solid organ transplantation in Western Australia.
Thompson G; Boan P; Baumwol J; Chakera A; MacQuillan G; Swaminathan S; Lavender M; Flexman J; James I; John M
Pathology; 2018 Aug; 50(5):554-561. PubMed ID: 29945729
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A
BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
Fleming T; Dunne J; Crowley B
J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
[TBL] [Abstract][Full Text] [Related]
4. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
[TBL] [Abstract][Full Text] [Related]
5. QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity.
Giulieri S; Manuel O
Expert Rev Mol Diagn; 2011 Jan; 11(1):17-25. PubMed ID: 21171917
[TBL] [Abstract][Full Text] [Related]
6. Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients.
Banas B; Böger CA; Lückhoff G; Krüger B; Barabas S; Batzilla J; Schemmerer M; Köstler J; Bendfeldt H; Rascle A; Wagner R; Deml L; Leicht J; Krämer BK
BMC Immunol; 2017 Mar; 18(1):15. PubMed ID: 28270092
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia.
Lisboa LF; Kumar D; Wilson LE; Humar A
Transplantation; 2012 Jan; 93(2):195-200. PubMed ID: 22179399
[TBL] [Abstract][Full Text] [Related]
8. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.
Gliga S; Korth J; Krawczyk A; Wilde B; Horn PA; Witzke O; Lindemann M; Fiedler M
J Clin Virol; 2018 Aug; 105():91-96. PubMed ID: 29936407
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients With a High Risk of CMV Disease (D+/R-): A Case Series.
Andreani M; Albano L; Benzaken S; Cassuto E; Jeribi A; Caramella A; Giordanengo V; Bernard G; Esnault V; Seitz-Polski B
Transplant Proc; 2020; 52(1):204-211. PubMed ID: 31889538
[TBL] [Abstract][Full Text] [Related]
10. Quantiferon-Cytomegalovirus assay: A potentially useful tool in the evaluation of CMV-specific CD8+ T-cell reconstitution in pediatric hematopoietic stem cell transplant patients.
Paouri B; Soldatou A; Petrakou E; Theodosaki M; Tsentidis C; Kaisari K; Oikonomopoulou C; Matsas M; Goussetis E
Pediatr Transplant; 2018 Aug; 22(5):e13220. PubMed ID: 29777573
[TBL] [Abstract][Full Text] [Related]
11. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation.
Lochmanova A; Lochman I; Tomaskova H; Marsalkova P; Raszka J; Mrazek J; Dedochova J; Martinek A; Brozmanova H; Grundmann M
Transplant Proc; 2010 Nov; 42(9):3574-7. PubMed ID: 21094818
[TBL] [Abstract][Full Text] [Related]
12. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
Martín-Gandul C; Pérez-Romero P; Blanco-Lobo P; Benmarzouk-Hidalgo OJ; Sánchez M; Gentil MA; Bernal C; Sobrino JM; Rodríguez-Hernández MJ; Cordero E;
Transpl Int; 2014 Oct; 27(10):1060-8. PubMed ID: 24964364
[TBL] [Abstract][Full Text] [Related]
13. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications.
Tey SK; Kennedy GA; Cromer D; Davenport MP; Walker S; Jones LI; Crough T; Durrant ST; Morton JA; Butler JP; Misra AK; Hill GR; Khanna R
PLoS One; 2013; 8(10):e74744. PubMed ID: 24146744
[TBL] [Abstract][Full Text] [Related]
14. Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience.
Favi E; Santangelo R; Iesari S; Morandi M; Marcovecchio GE; Trecarichi EM; Salerno MP; Ferraresso M; Citterio F; Romagnoli J
Transplant Proc; 2017 Oct; 49(8):1766-1772. PubMed ID: 28923622
[TBL] [Abstract][Full Text] [Related]
15. [Cytomegalovirus effects in solid organ transplantation and the role of antiviral prophylaxis].
Weclawiak H; Mengelle C; Ould Mohamed A; Izopet J; Rostaing L; Kamar N
Nephrol Ther; 2010 Nov; 6(6):505-12. PubMed ID: 20829141
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus (CMV) excretion as a factor in the severity of CMV disease in kidney and simultaneous kidney and pancreas transplantation.
Pouteil-Noble C; Ecochard R; Bosshard S; Lacavalerie B; Donia A; Landrivon G; Tardy JC; Dubernard JM; Aymard M; Touraine JL
Transpl Int; 1992; 5 Suppl 1():S26-9. PubMed ID: 14621724
[TBL] [Abstract][Full Text] [Related]
17. Analysis of spontaneous resolution of cytomegalovirus replication after transplantation in CMV-seropositive patients with pretransplant CD8+IFNG+ response.
Páez-Vega A; Poyato A; Rodriguez-Benot A; Guirado L; Fortún J; Len O; Abdala E; Fariñas MC; Cordero E; de Gracia C; Hernández D; González R; Torre-Cisneros J; Cantisán S; ;
Antiviral Res; 2018 Jul; 155():97-105. PubMed ID: 29782877
[TBL] [Abstract][Full Text] [Related]
18. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.
Abate D; Saldan A; Mengoli C; Fiscon M; Silvestre C; Fallico L; Peracchi M; Furian L; Cusinato R; Bonfante L; Rossi B; Marchini F; Sgarabotto D; Rigotti P; Palù G
J Clin Microbiol; 2013 Aug; 51(8):2501-7. PubMed ID: 23678073
[TBL] [Abstract][Full Text] [Related]
19. [Cytomegalovirus infection after heart transplantation. Retrospective analysis of an antiviral CMV prevention].
Antretter H; Höfer D; Klaus A; Larcher C; Margreiter J; Margreiter R
Dtsch Med Wochenschr; 2000 Apr; 125(15):445-51. PubMed ID: 10800441
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study.
Chanouzas D; Small A; Borrows R; Ball S
PLoS One; 2018; 13(3):e0193968. PubMed ID: 29558479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]